<DOC>
	<DOCNO>NCT00629187</DOCNO>
	<brief_summary>The goal study find maximum dose drug , temozolomide , safely give subject brain tumor . Past study show maximum dose temozolomide limit low blood count . The investigator use blood stem cell collect bone marrow help subject recover blood count , procedure call autologous stem cell transplant stem cell rescue . This way , investigator expect able safely deliver high dos temozolomide . This study available Tufts Medical Center .</brief_summary>
	<brief_title>Safety Study High Dose Temozolomide Treat Relapsed/Refractory Central Nervous System ( CNS ) Malignancy</brief_title>
	<detailed_description>High dose chemotherapy autologous stem cell transplant accept treatment alternative patient brain tumor . Temozolomide approve use United States Food Drug Administration ( FDA ) certain tumor brain . The dos temozolomide give study high approve FDA high give prior study . Over 25 subject enrol study period 5 year . This study available Tufts Medical Center .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients health care proxy must able provide consent participate trial . Patients must one follow diagnosis respond recurred follow least one prior chemotherapy regimen radiation therapy : anaplastic astrocytoma , glioblastoma multiforme oligodendroglioma primary CNS lymphoma malignant disease metastatic CNS Patients must candidate high dose chemotherapy autologous stem cell transplant accord follow criterion : Patients must age 18 70 year ( inclusive ) Patients must leave ventricular ejection fraction great equal 45 % MUGA echocardiogram Patients must adequate pulmonary function FEV1 , FVC DLCO great equal 50 % predicted Patients must serum direct bilirubin less equal 2.0 mg/dl transaminase less equal 3x institutional upper limit normal Patients must serum creatinine less equal 2 mg/dl creatinine clearance great equal 60 ml/min ( either calculate measure ) Patients must ECOG performance status 0 2 Patients must least 4 week last cytoreductive chemotherapy . Expected survival least 3 month Patients uncontrolled metastatic disease outside CNS would , investigator 's opinion , limit survival le 6 month Patients uncontrolled seizure ineligible . Patients history myocardial infarction within precede 6 month , significant arrhythmia within precede 3 month , uncontrolled hypertension congestive heart failure ineligible . Patients unstable angina ineligible . Pregnant lactate woman ineligible . Male female patient agree practice approve method birth control duration study ineligible . Patients uncontrolled , active infection ineligible . Patients infected HIV ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Lung Neoplasm</keyword>
	<keyword>Breast Neoplasm</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Central Nervous System Neoplasms</keyword>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>Neoplasm Second Primary</keyword>
	<keyword>Peripheral Blood Stem Cell Transplantation</keyword>
</DOC>